Article
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer discovery - 7 Jul 2023
Negrao Marcelo V, Araujo Haniel A, Lamberti Giuseppe, Cooper Alissa J, Akhave Neal S, Zhou Teng, Delasos Lukas, Hicks J Kevin, Aldea Mihaela, Minuti Gabriele, Hines Jacobi, Aredo Jacqueline V, Dennis Michael J, Chakrabarti Turja, Scott Susan C, Bironzo Paolo, Scheffler Matthias, Christopoulos Petros, Stenzinger Albrecht, Riess Jonathan W, Kim So Yeon, Goldberg Sarah B, Li Mingjia, Wang Qi, Qing Yun, Ni Ying, Do Minh Truong, Lee Richard, Ricciuti Biagio, Alessi Joao Victor, Wang Jing, Resuli Blerina, Landi Lorenza, Tseng Shu-Chi, Nishino Mizuki, Digumarthy Subba R, Rinsurongkawong Waree, Rinsurongkawong Vadeerat, Vaporciyan Ara A, Blumenschein George R, Zhang Jianjun, Owen Dwight H, Blakely Collin M, Mountzios Giannis, Shu Catherine A, Bestvina Christine M, Garassino Marina Chiara, Marrone Kristen A, Gray Jhanelle E, Patel Sandip Pravin, Cummings Amy L, Wakelee Heather A, Wolf Juergen, Scagliotti Giorgio Vittorio, Cappuzzo Federico, Barlesi Fabrice, Patil Pradnya D, Drusbosky Leylah, Gibbons Don L, Meric-Bernstam Funda, Lee J Jack, Heymach John V, Hong David S, Heist Rebecca S, Awad Mark M, Skoulidis Ferdinandos
Abstract excerpt
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non-small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these...
Read the complete abstract on PubMed